HopeStage
Back to all studies
CompletedNCT01941043

CERC-301 Added to Antidepressants for Severe Depression and Recent Suicidal Thoughts

About this titleRead the official source — NCT01941043
Medication studyAges 18–70United States
The study in practice

Understand this study

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.

Listed locations
Birmingham and 23 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateNovember 2013
Recruitment status
Completed
Enrollment listed in the registry
1,357
Sponsor
Avalo Therapeutics, Inc.
Sponsor type
Biotech company
Study type
Drug
Intervention type
Drug, Other
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 70 Years
Official registry ID
NCT01941043
Official title
Show the full official title

A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Birmingham · Phoenix · Culver City

21 more locations
  • Garden Grove
  • Glendale
  • National City
  • Oakland
  • Oceanside
  • San Diego
  • Jacksonville
  • North Miami
  • Orlando
  • Atlanta
  • Marietta
  • Chicago
  • Baltimore
  • O'Fallon
  • Mount Kisco
  • New York
  • Rochester
  • Canton
  • Media
  • Dallas
  • Bellevue

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Avalo Therapeutics, Inc.

Did this study involve medication?

Yes. The study involved medication, including CERC-301.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies